Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

ARD1 stabilization of TSC2 suppresses tumorigenesis through the mTOR signaling pathway.

Kuo HP, Lee DF, Chen CT, Liu M, Chou CK, Lee HJ, Du Y, Xie X, Wei Y, Xia W, Weihua Z, Yang JY, Yen CJ, Huang TH, Tan M, Xing G, Zhao Y, Lin CH, Tsai SF, Fidler IJ, Hung MC.

Sci Signal. 2010 Feb 9;3(108):ra9. doi: 10.1126/scisignal.2000590.

2.

Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis.

Wang Z, Wang Z, Guo J, Li Y, Bavarva JH, Qian C, Brahimi-Horn MC, Tan D, Liu W.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3053-8. doi: 10.1073/pnas.1113356109. Epub 2012 Feb 6.

3.

Phosphorylation of ARD1 by IKKbeta contributes to its destabilization and degradation.

Kuo HP, Lee DF, Xia W, Lai CC, Li LY, Hung MC.

Biochem Biophys Res Commun. 2009 Nov 6;389(1):156-61. doi: 10.1016/j.bbrc.2009.08.127. Epub 2009 Aug 28.

4.

Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.

Lu KH, Wu W, Dave B, Slomovitz BM, Burke TW, Munsell MF, Broaddus RR, Walker CL.

Clin Cancer Res. 2008 May 1;14(9):2543-50. doi: 10.1158/1078-0432.CCR-07-0321.

5.

Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.

Wen ZH, Su YC, Lai PL, Zhang Y, Xu YF, Zhao A, Yao GY, Jia CH, Lin J, Xu S, Wang L, Wang XK, Liu AL, Jiang Y, Dai YF, Bai XC.

Oncogene. 2013 Jan 10;32(2):160-70. doi: 10.1038/onc.2012.47. Epub 2012 Feb 20.

PMID:
22349822
6.

AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf, and TSC1/TSC2.

Lin HP, Lin CY, Huo C, Jan YJ, Tseng JC, Jiang SS, Kuo YY, Chen SC, Wang CT, Chan TM, Liou JY, Wang J, Chang WS, Chang CH, Kung HJ, Chuu CP.

Oncotarget. 2015 Sep 29;6(29):27097-112. doi: 10.18632/oncotarget.4553.

7.

TSC1 controls distribution of actin fibers through its effect on function of Rho family of small GTPases and regulates cell migration and polarity.

Ohsawa M, Kobayashi T, Okura H, Igarashi T, Mizuguchi M, Hino O.

PLoS One. 2013;8(1):e54503. doi: 10.1371/journal.pone.0054503. Epub 2013 Jan 23.

8.

Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.

Kim SH, Kowalski ML, Carson RP, Bridges LR, Ess KC.

Dis Model Mech. 2013 Jul;6(4):925-33. doi: 10.1242/dmm.011494. Epub 2013 Mar 27.

9.

Tuberous sclerosis complex tumor suppressor-mediated S6 kinase inhibition by phosphatidylinositide-3-OH kinase is mTOR independent.

Jaeschke A, Hartkamp J, Saitoh M, Roworth W, Nobukuni T, Hodges A, Sampson J, Thomas G, Lamb R.

J Cell Biol. 2002 Oct 28;159(2):217-24. Epub 2002 Oct 28.

10.

Tuberous sclerosis complex activity is required to control neuronal stress responses in an mTOR-dependent manner.

Di Nardo A, Kramvis I, Cho N, Sadowski A, Meikle L, Kwiatkowski DJ, Sahin M.

J Neurosci. 2009 May 6;29(18):5926-37. doi: 10.1523/JNEUROSCI.0778-09.2009.

11.

Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma.

Chakraborty S, Mohiyuddin SM, Gopinath KS, Kumar A.

BMC Cancer. 2008 Jun 6;8:163. doi: 10.1186/1471-2407-8-163.

12.

Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling.

DeYoung MP, Horak P, Sofer A, Sgroi D, Ellisen LW.

Genes Dev. 2008 Jan 15;22(2):239-51. doi: 10.1101/gad.1617608.

13.

Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.

Fuchs A, König K, Heukamp LC, Fassunke J, Kirfel J, Huss S, Becker AJ, Büttner R, Majores M.

Diagn Pathol. 2014 Mar 4;9:48. doi: 10.1186/1746-1596-9-48.

14.

Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex.

Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, Dong Z, Apte U, Pallet N, Johnson RL, Terzi F, Kwiatkowski DJ, Scoazec JY, Martignoni G, Pende M.

J Exp Med. 2014 Oct 20;211(11):2249-63. doi: 10.1084/jem.20140341. Epub 2014 Oct 6.

15.

REDD2 is enriched in skeletal muscle and inhibits mTOR signaling in response to leucine and stretch.

Miyazaki M, Esser KA.

Am J Physiol Cell Physiol. 2009 Mar;296(3):C583-92. doi: 10.1152/ajpcell.00464.2008. Epub 2009 Jan 7.

16.

Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.

Goncharova EA, Goncharov DA, Chisolm A, Spaits MS, Lim PN, Cesarone G, Khavin I, Tliba O, Amrani Y, Panettieri RA Jr, Krymskaya VP.

Mol Pharmacol. 2008 Mar;73(3):778-88. Epub 2007 Dec 19.

17.

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR.

Dere R, Wilson PD, Sandford RN, Walker CL.

PLoS One. 2010 Feb 16;5(2):e9239. doi: 10.1371/journal.pone.0009239.

18.

Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity.

Cicchini M, Chakrabarti R, Kongara S, Price S, Nahar R, Lozy F, Zhong H, Vazquez A, Kang Y, Karantza V.

Autophagy. 2014;10(11):2036-52. doi: 10.4161/auto.34398. Epub 2014 Oct 30.

19.

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.

Kwiatkowski DJ, Manning BD.

Hum Mol Genet. 2005 Oct 15;14 Spec No. 2:R251-8. Review.

20.

Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.

Mi R, Ma J, Zhang D, Li L, Zhang H.

J Genet Genomics. 2009 Jun;36(6):355-61. doi: 10.1016/S1673-8527(08)60124-1.

PMID:
19539245
Items per page

Supplemental Content

Write to the Help Desk